Patient Savings Program

Savings card available!

The reality of living with IBS-D

Watch Ask Me Anything.

VIBERZI patient brochure

Information about VIBERZI and IBS-D.

VIBERZI samples

Download the form to request samples.

Not eligible where prohibited by law.

Contraindications

VIBERZI is contraindicated in patients:

Warnings and Precautions
Pancreatitis:
Sphincter of Oddi Spasm:
Adverse Reactions
Indication

VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Please also see full Prescribing Information.

 
Important Safety Information and Indication
See More
Contraindications

VIBERZI is contraindicated in patients:

  • Without a gallbladder.
  • With known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction; a history of pancreatitis; or structural diseases of the pancreas.
  • With alcoholism, alcohol abuse, alcohol addiction, or who drink more than 3 alcoholic beverages per day.
  • With severe hepatic impairment.
  • With a history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.
Warnings and Precautions
Pancreatitis:
  • Pancreatitis, with or without sphincter of Oddi spasm, has been reported in patients taking either the 75 mg or 100 mg dosage of VIBERZI, including serious cases resulting in hospitalization, primarily in patients without a gallbladder. Fatal cases have also been reported in patients without a gallbladder. VIBERZI is contraindicated in patients without a gallbladder. Most of the reported cases of serious pancreatitis occurred within a week of starting treatment with VIBERZI and some patients developed symptoms after one to two doses.
  • In patients with a gallbladder, evaluate a patient’s alcohol intake prior to starting VIBERZI. Instruct patients to avoid chronic or acute excessive alcohol use while taking VIBERZI. Monitor for new or worsening abdominal pain that may radiate to the back or shoulder, with or without nausea and vomiting. Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of pancreatitis such as acute abdominal or epigastric pain radiating to the back or shoulder associated with elevations of pancreatic enzymes with or without nausea and vomiting.
Sphincter of Oddi Spasm:
  • There is a risk of sphincter of Oddi spasm, resulting in pancreatitis or hepatic enzyme elevation associated with acute abdominal pain (eg, biliary-type pain) in patients taking VIBERZI. Serious adverse reactions of sphincter of Oddi spasm with or without pancreatitis resulting in hospitalization have been reported, primarily in patients without a gallbladder. Cases of serious sphincter of Oddi spasm occurred within a week of starting treatment with VIBERZI and some patients developed symptoms after one to two doses.
  • Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of sphincter of Oddi spasm such as acute worsening of abdominal pain that may radiate to the back or shoulder with or without nausea or vomiting, associated with elevations of pancreatic enzymes or liver transaminases. Do not restart VIBERZI in patients who developed biliary duct obstruction while taking VIBERZI.
Adverse Reactions
  • The most commonly reported adverse reactions (incidence >5% and greater than placebo) were constipation, nausea, and abdominal pain.
Indication

VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Please also see full Prescribing Information.